Author(s): Akman A, Yilmaz E, Mutlu H, Ozdogan M
Abstract Share this page
Abstract Bevacizumab is a monoclonal antibody against vascular endothelial growth factor (VEGF), which is used to treat several cancers. Currently, experience with anti-VEGF treatment for psoriasis is limited, and no published reports on this use exist. We describe a patient with metastatic colon cancer and psoriasis who experienced complete remission of psoriasis during treatment with bevacizumab and combination chemotherapy without any other treatment for psoriasis. These data suggest that bevacizumab may be a promising therapeutic agent for the treatment of psoriasis.
This article was published in Clin Exp Dermatol
and referenced in Journal of Clinical & Experimental Dermatology Research